• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

艾滋病临床试验中CD4+细胞计数变化的评估。

Evaluation of change in CD4+ cell counts in AIDS clinical trials.

作者信息

Liang H

机构信息

Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA.

出版信息

Stat Methods Med Res. 2008 Apr;17(2):141-50. doi: 10.1177/0962280206075524. Epub 2007 Aug 14.

DOI:10.1177/0962280206075524
PMID:17698930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2832484/
Abstract

To evaluate the antiretroviral activity of antiretroviral agents and to compare the effects of two different antiretroviral agents, we propose a non-parametric mixed-effects model to investigate change of CD4+ counts. The proposed model and methods are applied to analyse the data from PACTG345 study. Population and individual patterns of change of CD4+ counts and a reference band are obtained. Our results indicate that treatment with high-dose ritonavir is significantly superior compared with low-dose ritonavir.

摘要

为评估抗逆转录病毒药物的抗逆转录病毒活性并比较两种不同抗逆转录病毒药物的效果，我们提出一种非参数混合效应模型来研究CD4 +细胞计数的变化。将所提出的模型和方法应用于分析来自PACTG345研究的数据。获得了CD4 +细胞计数变化的总体和个体模式以及一个参考区间。我们的结果表明，高剂量利托那韦治疗显著优于低剂量利托那韦。

相似文献

1
Evaluation of change in CD4+ cell counts in AIDS clinical trials.艾滋病临床试验中CD4+细胞计数变化的评估。
Stat Methods Med Res. 2008 Apr;17(2):141-50. doi: 10.1177/0962280206075524. Epub 2007 Aug 14.
2
Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.核苷类似物联合利托那韦用于接受稳定抗逆转录病毒治疗的有经验的HIV感染儿童：一项随机对照试验。儿科艾滋病临床试验组338研究团队。
JAMA. 2000 Jan 26;283(4):492-8. doi: 10.1001/jama.283.4.492.
3
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.利用 CD4 细胞计数预测基于达芦那韦的高效抗逆转录病毒治疗第一年的 HIV 护理直接成本：POWER 的证据。
Pharmacoeconomics. 2010;28 Suppl 1:169-81. doi: 10.2165/11587510-000000000-00000.
4
The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.接受抗逆转录病毒治疗3年后病毒载量无法检测的患者每日一次服用沙奎那韦/利托那韦的48周疗效。
HIV Med. 2005 Mar;6(2):122-8. doi: 10.1111/j.1468-1293.2005.00274.x.
5
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.基于对CD4细胞计数和HIV RNA的治疗效果预测利托那韦增强型TMC114的临床益处。
HIV Med. 2007 May;8(4):234-40. doi: 10.1111/j.1468-1293.2007.00466.x.
6
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.抗逆转录病毒治疗。成人HIV感染：定义更明确的一线治疗。
Prescrire Int. 2004 Aug;13(72):144-50.
7
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.美国达芦那韦/利托那韦 600/100mg bid 在 TITAN 试验中纳入有蛋白酶抑制剂耐药证据的治疗经验丰富的 HIV 感染成人中的成本效益。
Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.
8
Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.在围产期感染HIV-1的儿童中，使用奈非那韦或洛匹那韦/利托那韦方案的免疫恢复动力学不同。
Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35. doi: 10.1177/039463200501800416.
9
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):483-7. doi: 10.1097/00126334-200212150-00005.
10
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.洛匹那韦/利托那韦用于接受过治疗的垂直感染HIV儿童的高效抗逆转录病毒疗法的长期疗效
J Antimicrob Chemother. 2008 Jan;61(1):183-90. doi: 10.1093/jac/dkm436. Epub 2007 Nov 19.

引用本文的文献

1
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.从包含 HIV 核苷逆转录酶抑制剂（NRTI）加蛋白酶抑制剂的方案转换为包含 NRTI 加非 NRTI 或仅 NRTI 的方案后，CD4+ T 细胞计数的长期演变。
BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23.

本文引用的文献

1
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.恩曲他滨和拉米夫定用于HIV感染病情稳定受抑制患者的随机研究。
AIDS. 2004 Nov 19;18(17):2269-76. doi: 10.1097/00002030-200411190-00007.
2
Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.具有信息性缺失和左删失的双变量纵向数据的联合建模及其在HIV感染治疗中CD4 +细胞计数和HIV RNA病毒载量演变中的应用。
Stat Med. 2005 Jan 15;24(1):65-82. doi: 10.1002/sim.1923.
3
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras.法国HIV相关隐球菌病的流行病学（1985 - 2001年）：高效抗逆转录病毒治疗时代前后的比较
AIDS. 2004 Feb 20;18(3):555-62. doi: 10.1097/00002030-200402200-00024.
4
Dual HIV-1 infection associated with rapid disease progression.双重HIV-1感染与疾病快速进展相关。
Lancet. 2004 Feb 21;363(9409):619-22. doi: 10.1016/S0140-6736(04)15596-7.
5
Joint modelling of longitudinal measurements and event time data.纵向测量数据与事件时间数据的联合建模
Biostatistics. 2000 Dec;1(4):465-80. doi: 10.1093/biostatistics/1.4.465.
6
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants.在年轻的HIV-1感染婴儿中，很少检测到HIV-1特异性而非巨细胞病毒特异性的CD8(+) T细胞反应。
J Immunol. 2001 Dec 15;167(12):7134-40. doi: 10.4049/jimmunol.167.12.7134.
7
Nonparametric mixed effects models for unequally sampled noisy curves.用于非等距采样噪声曲线的非参数混合效应模型。
Biometrics. 2001 Mar;57(1):253-9. doi: 10.1111/j.0006-341x.2001.00253.x.
8
Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.高效抗逆转录病毒治疗开始后HIV-1感染者的炎症反应
Ann Intern Med. 2000 Sep 19;133(6):447-54. doi: 10.7326/0003-4819-133-6-200009190-00013.
9
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.人类免疫缺陷病毒1型RNA水平和CD4计数作为预后标志物及替代终点：一项荟萃分析。HIV替代标志物协作组
AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1123-33. doi: 10.1089/088922200414965.
10
Natural immunity and HIV disease progression.
AIDS. 1999 Apr 1;13(5):557-63. doi: 10.1097/00002030-199904010-00004.